4-hydroxyclomiphene has been researched along with ly 117018 in 2 studies
| Studies (4-hydroxyclomiphene) | Trials (4-hydroxyclomiphene) | Recent Studies (post-2010) (4-hydroxyclomiphene) | Studies (ly 117018) | Trials (ly 117018) | Recent Studies (post-2010) (ly 117018) |
|---|---|---|---|---|---|
| 7 | 0 | 1 | 105 | 0 | 0 |
| Protein | Taxonomy | 4-hydroxyclomiphene (IC50) | ly 117018 (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 0.12 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, M; Sutherland, RL | 2 |
2 other study(ies) available for 4-hydroxyclomiphene and ly 117018
| Article | Year |
|---|---|
Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation.
Topics: Breast Neoplasms; Calcitriol; Cell Division; Cell Line; Clomiphene; Drug Synergism; Estradiol; Estrogen Antagonists; Female; Humans; Kinetics; Pyrrolidines; Receptors, Calcitriol; Receptors, Estradiol; Receptors, Steroid; Tamoxifen; Thiophenes; Tretinoin | 1991 |
Epidermal growth factor partially reverses the inhibitory effects of antiestrogens on T 47D human breast cancer cell growth.
Topics: Breast Neoplasms; Cell Division; Cell Line; Clomiphene; Epidermal Growth Factor; Estrogen Antagonists; Humans; Pyrrolidines; Tamoxifen; Thiophenes | 1987 |